Target RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024

DURHAM, N.C., Dec. 3, 2024 /PRNewswire/ -- Target RWE, a leader in real-world evidence solutions in liver disease, presented important research on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting, November 15-19 in San Diego, CA. Leveraging data from Target RWE's metabolic dysfunction–associated steatohepatitis (MASH) patient cohort, the study highlights the potential of GLP-1 RAs to slow disease progression and reduce mortality among patients with MASLD.